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Abstract
The gene encoding for core-binding factor B (CBFB) is altered
in acute myeloid leukemia samples with an inversion in
chromosome 16, expressing the fusion protein CBFB-SMMHC.
Previous studies have shown that this oncoprotein interferes
with hematopoietic differentiation and proliferation and
participates in leukemia development. In this study, we
provide evidence that CbfB modulates the oncogenic function
of this fusion protein. We show that CbfB plays an important
role in proliferation of hematopoietic progenitors expressing
CbfB-SMMHC in vitro . In addition, CbfB-SMMHC–mediated
leukemia development is accelerated in the absence of
CbfB. These results indicate that the balance between CbfB
and CbfB-SMMHC directly affects leukemia development, and
suggest that CBF-specific therapeutic molecules should target
CBFB-SMMHC function while maintaining CBFB activity.
(Cancer Res 2006; 66(23): 11214-8)
Introduction
The core-binding factor (CBF) transcription factor is the most
common target of chromosomal rearrangements in human acute
myeloid leukemia (AML), including the fusion genes CBFB-MYH11
and RUNX1-ETO (1). Moreover, RUNX1 is frequently mutated in
AML. CBF is a heterodimeric transcription factor that consists of a
DNA binding a-subunit, encoded by one of three members of the
RUNX family (RUNX1, RUNX2 , and RUNX3), and a h-subunit
encoded by the CBFB gene that increases DNA-binding affinity to
the complex. In hematopoiesis, the CBF heterodimer Cbfh:Runx1
regulates expression of genes with critical functions in differenti-
ation of lymphoid and myeloid lineages. The Cbfh:Runx3 complex
is involved in B-cell maturation and the silencing of the CD4 gene
during T-cell maturation (2). Studies in the mouse have determined
that Cbfb/ and Runx1/ embryos fail to develop embryonic
definitive hematopoiesis and die at midgestation (3–6). This pheno-
type was rescued in Cbfb/ mice expressing Cbfb from the hema-
topoietic specific promoters Tie2 or GATA1 , further underscoring
the key role of Cbfh during hematopoietic differentiation (7, 8).
Approximately 12% of AML patients present a chromosome 16
inversion [inv(16); ref. 9] that breaks and joins the first five exons of
CBFB with the second half of the smooth muscle myosin heavy
chain gene MYH11 (10). The resulting CBFB-MYH11 gene encodes
the CBFh-SMMHC fusion protein, which retains the Runx-binding
domain from Cbfh and multimerization domain from the myosin
sequence. Studies in mice have shown that Cbfh-SMMHC is a
dominant inhibitor of CBF function because Cbfb+/MYH11 hetero-
zygous knock-in embryos expressing the fusion protein failed
to develop definitive hematopoiesis (11), as was shown for the
Cbfb- and Runx1-null embryos (3–6).
Induction of Cbfh-SMMHC expression or Runx1-loss in adult
bone marrow does not seem to affect the maintenance of long-
term hematopoietic stem cells (12–14). However, Cbfh-SMMHC
expression reduces hematopoietic stem cell function by inhibiting
multilineage repopulation and creating a myeloid progenitor
predisposed to leukemia development (11).
Several lines of evidence suggest that Cbfh-SMMHC may exert
an incomplete block of CBF function. First, ectopic expression of
the fusion protein in embryonic stem cells expressing one or both
copies of Cbfb does not inhibit differentiation in vitro (15). Second,
Cbfb+/MYH11 knock-in hematopoietic stem cells expressing Cbfh-
SMMHC persist in the bone marrow of the chimeras (16). Third,
retroviral insertional mutagenesis in Cbfb+/MYH11 knock-in chime-
ras identified common insertions in the Runx2 gene (17), suggest-
ing that Cbfh-SMMHC leukemic function is affected by levels of
Runx proteins.
In this study, we test the hypothesis that Cbfh modulates the
Cbfh-SMMHC effect in adult hematopoiesis and leukemogenesis.
We used mice with a Cbfb knock-out allele and a conditional
Cbfb-MYH11 knock-in allele to study adult myeloid differentiation
and leukemia progression. This study provides evidence that Cbfh
modulates hematopoietic differentiation and Cbfh-SMMHC–
mediated leukemia development, and suggests that CBFh up-
regulation may efficiently counteract differentiation defects in
human AML with inv(16).
Materials and Methods
Generation of triple Mx1Cre/Cbfb/MYH11 transgenic mice. The
design of the conditional Cbfb+/MYH11 knock-in mice has previously been
described (12), with the exception that monoclonal h-actin antibody
(Sigma, St. Louis, MO) was used as western blot control. Expression of
CBFh-SMMHC was induced in 3-week-old mice by activation of Cre
recombinase from the Mx1Cre transgene using one to three doses of
polyinosinic-polycytidylic acid (pIpC) every other day (18). Heterozygous
Cbfb/+ knockout mice were generously provided by Nancy Speck
(Dartmouth Medical School, Hanover, NH; ref. 4). For this study, all mice
were maintained in the 129SvEv strain. In the transplantation assays,
1  106 leukemic cells were transplanted into sublethally irradiated
syngenic recipients as described elsewhere (19).
Molecular and cytology analysis. The Western blot, flow cytometry,
and histopathology analyses were done as previously described (12).
Fluorescence-activated cell-sorting analysis was done in peripheral blood
of leukemic mice using FITC-c-kit and phycoerythrin-lineage antibodies
(Lin+: B220, CD3, Gr1, and Mac1; all from BD Biosciences, San Jose, CA).
Colony forming assays.Mice with the genotypes Cbfb+/56M, Cre;Cbfb+/56M,
Cbfb-/56M , and Cre;Cbfb-/56M were injected with pIpC at weaning every
other day. Two days after the second injection, bone marrow cells were
Requests for reprints: Lucio H. Castilla, Program in Gene Function and
Expression, University of Massachusetts Medical School, 364 Plantation Street, LRB/
622, Worcester, MA 01605. Phone: 508-856-3281; Fax: 508-856-5460; E-mail: Lucio.
Castilla@umassmed.edu.
I2006 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-06-0959
Cancer Res 2006; 66: (23). December 1, 2006 11214 www.aacrjournals.org
Research Article
harvested, and 1  104 WBC were plated in duplicate in methylcellulose
supplemented with cytokines interleukin (IL)-3, IL-6, and stem cell factor and
erythropoietin (Methocult-3434, Stem Cell Technologies, Vancouver, Canada)
in 35-mm nontreated tissue culture dishes (Corning). The number of myeloid
colonies was scored at day 7. Single colonies were harvested and either
cytospun for cytology analysis or placed into lysis buffer for PCR analysis.
Statistical considerations. Differences in survival functions between
groups were evaluated by Kaplan-Meier product limit survival analysis
using the Tarone-Ware test to test the hypothesis of overall equivalence. In
the presence of significant overall differences, pairwise comparisons were
made between the noncontrol groups using Tarone-Ware tests with a Sidak
adjustment to compensate for the additive type I error due to multiple
comparisons.
Analysis of human AML samples. Patients had a diagnosis of primary
AML, confirmed by cytologic examination of blood and bone marrow. After
informed consent, bone marrow aspirates or peripheral blood samples were
taken at diagnosis (n = 285) and processed for Affymetrix U133A GeneChip
analysis (20). For PCR and sequence analyses, cDNA prepared from 50 ng
of RNA was used for all PCR amplifications. The CBFB coding region
was sequenced for 27 inv(16)+ AML samples by cDNA amplification using
the primers CBFB-FOR 5¶-CAGAGAAGCAAGTTCGAGAACG-3¶ with CBFB-
REV 5¶-GTTTGAGGTCATCACCACCAC-3¶ and CBFB-FOR with CBFB6
5¶-GTCTTGTTGTCTTCTTGCCAG-3¶ (25 mmol/L deoxynucleotide triphos-
phate, 15 pmol primers, 2 mmol/L MgCl2, Taq polymerase and 10 buffer;
Invitrogen Life Technologies, Breda, the Netherlands). Cycling conditions for
both primer sets consisted of a denaturing cycle for 5 minutes at 94jC
followed by 30 cycles for amplification (1 minute 94jC, 1 minute 62jC,
1 minute 72jC), and a final extension cycle for 7 minutes at 72jC. PCR
products were purified using the Multiscreen-PCR 96-well system (Millipore,
Bedford, MA) followed by direct sequencing with CBFB-FOR, CBFB-REV,
and CBFB6 using an ABI-PRISM3100 genetic analyzer (Applied Biosytems,
Foster City, CA).
Results
CbfB is essential to maintain proliferation capacity of
myeloid progenitor cells expressing CbfB-SMMHC. We have
recently shown that bone marrow cells expressing Cbfh-SMMHC
accumulate abnormal myeloid progenitors able to form myeloid
colonies in vitro (12). To assess whether this effect is dependent on
the presence of Cbfh, colony-forming unit (CFU) assays were done
with bone marrow cells from heterozygous floxed (Cbfb+/56M),
hemizygous floxed (Cbfb-/56M), heterozygous restored (Cbfb+/MYH11),
and hemizygous restored (Cbfb/MYH11) mice (Fig. 1). The switch
from Cbfh to Cbfh-SMMHC expression (switching floxed to
restored allele) was induced by pIpC-mediated Cre activation
using the Mx1Cre transgene.
The number of myeloid and erythroid colonies was significantly
reduced in hemizygous restored bone marrow progenitor cells
expressing Cbfh-SMMHC when compared with control groups
(Fig. 2A). Considering that the loss of one Cbfb allele did not affect
CFU formation (heterozygous floxed versus hemizygous floxed),
these results indicate that the number of CFUs is markedly reduced
at Cbfb levels below 50%. In addition, the size of the colonies was
markedly reduced in hemizygous restored progenitors when
compared with controls (Fig. 2B). The Cre-lox–mediated excision
in CFUs from hemizygous restored plates was confirmed by PCR
analysis (data not shown). Cytology analysis of day-7 CFUs revealed
the presence of all myeloid forms, with a small but consistent
increase of blastlike immature cells in hemizygous restored
colonies (Fig. 2C). These results revealed that the loss of Cbfh in
the context of Cbfh-SMMHC significantly reduces the proliferation
capacity of bone marrow myeloid progenitors in vitro .
Hemizygous bone marrow cells expressing CbfB-SMMHC
show higher susceptibility to AML. The Cbfb+/MYH11 restored
mice succumb to AML with a median latency of 5 months (12).
This latency is dose dependent as mice induced with three pIpC
doses developed AML with a median latency of 5 months, mice
induced with one pIpC dose had AML with a median latency of
8 months, and uninduced mice remained disease-free.
To test whether the presence of Cbfh has an effect in Cbfh-
SMMHC–mediated AML, we compared heterozygous restored and
hemizygous restored mice after treatment with three doses of pIpC.
In the absence of Cbfh, 100% of mice with bone marrow cells
expressing Cbfh-SMMHC developed AML with a significant
Figure 1. Cbfb alleles used in this study. Exons 1 to 6 of the Cbfb gene are shown in boxes, and the encoded protein is shown on the right. The Cbfb knock-out
allele includes a neomycin (N) gene fused to the 3¶-end of exon 5 (4). The floxed Cbfb56M allele includes exons 5 and 6 and a hygromycin gene (H ) between
loxP sites (triangle ), followed by exon 5 fused to the 3¶ MYH11 sequence and a neomycin gene (12). Upon Cre-mediated loxP deletion, Cbfh-SMMHC is induced in
the CbfbMYH11 restored allele.
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acceleration of disease onset (median latency of 1.5 F 0.5 months;
P < 0.00001; Fig. 3A). Surprisingly, uninduced Mx1Cre/Cbfb-/56M
mice also developed AML with similar latency to that of induced
group (Fig. 3A ; red dashed line, uninduced; red solid line, induced).
It has previously been reported that Cre expression from the
Mx1Cre transgene is leaky in mice not treated with pIpC (21).
In our study, all AML samples from induced and uninduced groups
exhibited deletion of the floxed sequence by PCR analysis (data not
shown) and Cbfh-SMMHC expression was detected by Western
blot analysis (Fig. 3B). Furthermore, secondary transplantation of
Cbfb/MYH11 AML cells derived from induced or uninduced mice
produced leukemia in sublethally irradiated recipients with a
median latency of 6 weeks (data not shown). These results indicate
that Cbfh-SMMHC–induced AML development is accelerated in
the absence of Cbfh.
Disease pathology is dictated by CbfB-SMMHC. The hemizy-
gous restored leukemic Cbfb/MYH11 mice presented an increase in
WBC count (mean, 41.7 F 74.7  106/mL) when compared with
healthy littermates (mean, 4  106/mL). As previously described in
heterozygous restored leukemic mice, the leukemic cells from the
hemizygous mice included predominant blastlike and myelomo-
nocytic cells (Fig. 3C, top row) with the characteristic cell-surface
profile c-kit+/Lin (Fig. 3D ). Disease was also marked by
progressive anemia and infiltration into other organs, including
the spleen and liver. Histology analysis of these organs confirmed
the disruption of splenic architecture marked by infiltration of
leukemic cells (Fig. 3C, middle row) and focal infiltrations of
leukemic cells into the interstitial spaces of the liver (Fig. 3C,
bottom row). Compromise of the thymus and lymph nodes was not
observed. Taken together, the pathology of disease in hemizygous
and heterozygous mice was similar, suggesting that the AML
phenotype was determined by Cbfh-SMMHC.
The wild-type CBFB allele is not a frequent target of
mutations in inv(16) AML. To assess whether CBFB is frequently
altered in human CBF AML samples, expression and mutation
analyses of CBFB were undertaken. Sequence analysis of the CBFB
coding region in a panel of 29 inv(16) AML samples identified
no mutations. Expression analysis of CBFB in a panel of 285 human
AML samples indicated that inv(16) AML samples had a 40%
reduction in CBFB transcript when compared with CD34+ bone
marrow cells (relative value, 0.4 F 0.08), as expected by the
expression of one CBFB allele. The CBFB levels in t(8;21) and non-
CBF cytogenetic groups were unchanged [t(8;21) relative value,
0.9 F 0.23; non-CBF relative value, 1.0 F 0.32]. These results
indicate that the remaining CBFB allele is not frequently altered in
inv(16) AMLs.
Discussion
Endogenous expression of Cbfh and Cbfh˜-SMMHC from the
Cbfb allele of conditional knock-in mice creates a leukemia
precursor that progresses to AML in a multistep process (12).
Although the fusion protein is thought to act as a dominant factor
in differentiation and transformation (11, 12, 16), the role of Cbfh in
Figure 2. Cbfh modulates bone marrow myeloid proliferation in vitro . Colony forming assays in methylcellulose cultures using 1  104 bone marrow progenitor
cells with heterozygous floxed (+/56M), heterozygous restored (+/MYH11 ), hemizygous floxed (/56M), or hemizygous restored (/MYH11 ) Cbfb genotypes.
A, erythroid colonies were scored at day 4 (gray ) and myeloid colonies at day 4 (black ) and day 7 (white ). Columns, number of colonies from three independent
experiments, each in duplicate. B, representative images of colony size (amplification, 50). C, histogram representation of cytology analysis of CFU-GEMM,
CFU-Blast, CFU-GM, CFU-M, and CFU-G.
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Cbfh-SMMHC–mediated leukemia is not clear. Here we showed
that the capacity of Cbfh-SMMHC to induce AML in mice is
modulated by Cbfh.
The presence of Cbfh is critical for embryonic definitive
hematopoiesis (4) and for in vitro myeloid differentiation from
Cbfb/ embryonic stem cells (15). Our study indicates that Cbfh is
necessary for in vitro myeloid-erythoid differentiation of bone
marrow hematopoietic progenitors. In addition, because colonies
were drastically reduced in the absence of Cbfh but not in the
presence of Cbfh-SMMHC, our results support the hypothesis
that Cbfh-SMMHC may have an incomplete effect in differentia-
tion. As Cbfh and Cbfh-SMMHC compete for binding with Runx
proteins in bone marrow cells, basal levels of Cbfh:Runx1 complex
in hematopoietic progenitors expressing Cbfh-SMMHC may be
critical for proliferation of myeloid progenitors and delayed
transformation.
Endogenous expression of Cbfh-SMMHC and Cbfh in bone
marrow induces AML with a median latency of 5 months (12).
We observed that upon Cre-lox–mediated switch from Cbfh to
Cbfh-SMMHC expression in progenitor cells lacking a wild-type
Cbfb allele, AML latency was shortened to 6 weeks. These results
strongly suggest that Cbfh-SMMHC function is enhanced by Cbfh
loss. Surprisingly, a similar AML latency was observed between
induced and uninduced groups. Probably, a small progenitor
population may have undergone Cre/lox deletion due to ‘‘leaky’’
Cre expression from theMx1Cre transgene (21), and thus becoming
Figure 3. Loss of Cbfh accelerates Cbfh-SMMHC–mediated AML. A, Kaplan-Meier survival curve of mice expressing Cbfh-SMMHC in the presence or absence of
Cbfh. Mice induced with pIpC (+) heterozygous restored [red dotted line, +/MYH11;Cre (+) ; n = 38], uninduced () heterozygous floxed [black line with star mark,
+/56M () ; n = 20], uninduced hemizygous floxed [black line with circle mark, /56M () ; n = 15], untreated hemizygous restored [red dashed line, /MYH11 ;
Cre () ; n = 20], or treated hemizygous restored [red solid line, /MYH11;Cre (+) ; n = 16]. B, Western blot analysis of Cbfh-SMMHC and h-actin in AML samples
derived from restored Cbfb mice induced (+) with pIpC or uninduced (). The Cbfb genotype of the AML cells is shown on the top. C, disease pathology analysis
depicting an increase of immature leukemic cells (top row ; triangle, blastlike; arrow, myeloid form; magnification, 1,000), disruption of spleen architecture (middle row ;
magnification, 100), and the presence of infiltrating leukemia cells (white arrow ) in the liver (bottom row ; magnification, 100). Cells analyzed from wild-type
control (left column) and leukemic mice expressing Cbfh-SMMHC in the presence (middle column ) or absence (right column ) of Cbfh. D , FACS analysis of leukemic
cells from hemizygous restored mice (bottom ) compared with wild type control (top ) using lineage markers (Gr1, B220, Mac1, CD3) and a progenitor marker (c-kit).
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a leukemia precursor. Importantly, all AML samples presented Cre-
mediated deletion, suggesting that transformation is due to the Cbfh
to Cbfh-SMMHC switch. Furthermore, the finding that CBFb is not
frequently lost in human AML argues against its role as an inv(16)
cooperating tumor suppressor in AML. Rather, our results suggest
that increase in the Cbfh-SMMHC-to-Cbfh ratio reduced prolifer-
ation of myeloid progenitors while increasing their susceptibility to
neoplastic transformation, although the underlying mechanism is
unclear. However, we cannot rule out the possibility that
Cbfb loss in bone marrow could induce AML. The generation of
conditional Cbfb knock-out alleles will provide a critical tool to
directly address this possibility using a genetic approach.
Finally, these findings have important implications on the design
of targeted therapies. One potential avenue is the identification of
drugs that inhibit the fusion protein. Although candidate molecules
should act to disrupt Cbfh-SMMHC:Runx1 binding, it will be
critical that CBFh:Runx1 binding remains unaltered.
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